The issue of clarithromycin and increased cardiac deaths #4 - Where are the potential sources of variability?

1. Bioavailability
Regardless of its touted lipophilicity, clarithromycin has a reported average bioavailability of only about 50%. Generally, as a guiding principle, the lower the bioavailability, the greater the potential for variability in systemic availability.

2. Uncertain target site concentrations
There are two associated problems here.

Firstly, clarithromycin has an elimination half life of about 3-5 hours at low doses and 5-7 at higher doses. At a 12 hourly dosing intervals, there will be significant fluctuations in the plasma concentration profile. Even if it is administered at 8 hourly intervals, and if half-life is assumed to be at the high end of the range, say 8 hours, there will be at least a 2 fold fluctuation between peaks and trough. While this may meet the needs of anti-bacterial efficacy (assuming we keep trough levels above MIC), the levels of the peaks may predispose to cardiac toxicity if it is able to inhibit HERG potassium channels. To some extent, we can mitigate the fluctuations by using extended release formulations, but this may be at the expense of even more variability in bioavailability.

[source:http://medlibrary.org/lib/images-rx/clarithromycin-24/img-0238.jpg]

Comparison between normal formulation and extended release formulations

Secondly, since we do not routinely measure either plasma or tissue concentrations, we have little idea if adequate concentrations are being achieved at the target site. Here, there is some more uncertainty. Tissue and cellular concentrations tend to be higher than plasma unbound concentrations, but concentrations in the extra-cellular fluid (where the bugs are) are variable and may be lower than unbound concentrations of clarithromycin. These are functions of variable protein binding and the variable net activities of specific influx and efflux membrane transporters.

Consequent upon the previous two points, the differential effects of clarithromycin on the bacteria and on HERG channels may be variable between individuals not only because they relate to different effect compartments but the latter may relate to heights of the peak while the former to trough concentrations being above the MIC.

[Source:http://www.fda.gov/ohrms/dockets/ac/03/briefing/Image66.gif]

Relationship between QT prolongation ad clarithromycin concentrations

Although the IC50 for clarithromycin on the HERG channel is about a 100 times higher than the MIC, arrhythmic risk is associated with lower extent of inhibition. Hence cardiac risk is seen at much lower IC10 or IC20 concentrations

Added to all these, is the uncertainty contributed by an active 14-OH metabolite of clarithromycin.

3. Inter-individual variability in pharmacokinetics
Clarithromycin is both a substrate and inhibitor of CYP3A4. This metabolic pathway is also responsible to generating the active 14-OH metabolite. Variable CYP3A4 activity therefore results in a variable mix of clarithromycin and its active 14-OH metabolite.

There is a very high extent of variabilty in CYP3A4 activity in any population studied. There are also significant differences in activity between men and women (women generally higher). While there are genetic polymorphisms associated with CYP3A4, no single genetic variant has been able to account for the variability within a population. On the other hand, CYP3A4 is also vulnerable to many food and drug interactions.

To make matters more complicated, clarithromycin inhibits its own metabolism by CYP3A4, and exhibits a non-linear pharmacokinetic profile.

4. Inter-individual variability in susceptibility to QT prolongation
The HERG potassium channel gene is genetically polymorphic and variants may predispose to variable susceptibility to QT prolongation. Added to this is the uncertainty about appropriate dosing regiments between different ethnic populations, who may have different body weights and distributional volumes, as well as different exposures to CYP3A4 food and drug interactions.

5. Variability in microbial susceptibility
Apart from differences in anti-microbial efficacy due to variability in drug permeation to target sites, bacteria do differ in how susceptible they are to concentrations of clarithromycin. While sensitive bacteria generally have MICs in easily achievable range, resistance genes have become more prevalent and differences in bacterial sensitivity has become more common.

6. Compliance issues
One must never forget the variability that may be caused by failure of the patient to medicate according to instructions, leading to highly irregular dosing intervals and therefore variable degree of fluctuations in circulating drug concentrations.


Taking all these uncertainties into consideration, the question is how to ensure the patient gets optimal dosing? Think about it.

[To be continued]

Arylamine N-acetyltransferase 2 (NAT2)

One of the earliest demonstrations of a pharmacogenetic problem affecting therapeutic agents was that of the N-acetyltransferase enzyme. This is an enzyme that N-acetylates arylamines carcinogens and heterocyclic amines. In 1960, it was reported that the metabolism of the anti-TB drug isoniazid was bimodality distributed in the population. Patients could be distiguished into slow and rapid acetylator phenotypes by exposing them to either isoniazid or some other arylamine and measuring their acetylator status (typically the ratio of acetyl-metabolite/parent compound in either plasma or urine). The enzyme was eventually called N-acetyltransferase 2 (NAT2).

The frequency of slow acetylators varied considerably across the world. Caucasian populations generally have about 50% frequency of slow acetylators, while East Asians such as Chinese and Japanese had about 20-30% slow acetylators.

For many years after the discovery of this genetic polymorphism, drug companies avoided developing drugs which were substrates of NAT2, until it became increasingly recognized in the 1980's that NAT2 wasn't the only genetic polymorphism affecting drug metabolism. With the discovery of genetic polymorphisms affecting pretty much all drug metabolism pathways, the strategy shifted to management of pharmacogenetic problems, rather than just avoiding it.

Pharmacogenetics and genetic polymorphisms

In the theoretically correct application of the term, Pharmacogenetics is the study of inherited variations in drug response. Strictly, it would apply to germ line mutations (genetic polymorphisms) and not to somatic mutations or to epigenetic mechanisms (unless these can be inherited).

Genetic polymorphism occurs when the "simultaneous occurrence in the same locality of two or more alleles is in such proportions that the rarest of them cannot be maintained just by recurrent mutation". This conventionally assumes that the rarest allele should be more than 1%.

There are two parts to this definition.

a] it must refer a population in equilibrium; although I use this term guardedly, since no population is static and is truly ever in 'equilibrium'.

b] the frequency of the rarest allele is at least 1%. This is very empirical as it is not certain what is the barest minimum frequency for the allele to be propagatable in a given population. It would seem that 1% is too high a value, and genetic polymorphisms do refer to alleles with frequencies much less than 1%. It does not however, include mutations that occur sporadically and randomly. Consequently allele frequencies for a genetic polymorphism are often tested against the Hardy-Weinberg Equilibrium. If it does not fit the HWE, it does not necessarily mean it is not a genetic polymorphism. It just cautions the investigator to look reasons why the HWE has been violated.

One particular consideration that is often overlooked in determining allele frequencies in a genetic polymorphism (which may or may not cause deviations from the HWE), is whether the population is stable and if there is a real equilibrium with respect to the transmission of alleleic variants. This is a particular problem for Singapore, whose population has been growing at a phenomenal rate through immigrations, and the expansion of our foreign worker pool. Recent additions to the population now may begin to outnumber those that are born locally. This raises questions about whether the population genetic pool is too labile to be in any sort of equilibrium. It could only be if we are able to assume that the larger population base of people of similar "race/ethnicity" are in equilibrium globally. But this is not a valid assumption.